Oncolytics Biotech Inc. · NASDAQ:ONCY
Oncolytics Biotech — Investor Presentation (August 2016)
26 slides from Oncolytics Biotech's investor presentation, August 2016
Slide 1: Corporate Presentation
Corporate Presentation August 2016
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains certain forward looking statements relating to the Company’s financial results, business prospects, and the development and commercialization of REOLYSIN®, a therapeutic reovirus. These statements are based on management’s current expectations an
Slide 3: Oncolytics Overview
Oncolytics Overview Developing REOLYSIN® 400+ issued patents and (oncolytic virus) as a 70+ pending cancer therapeutic applications worldwide Conducted 30+ clinical 1,100+ patients treated; studies in 13 indications strong safety profile Manufacturing $20.41 million total at commercial scale current
Slide 4: What is REOLYSIN?
What is REOLYSIN®? A proprietary isolate of wild-type reovirus Serotype 3 Dearing Non-pathogenic Most humans show evidence of exposure by adulthood 4
Slide 5: Safety Profile of REOLYSIN
Safety Profile of REOLYSIN® General Safety 1,100+ patients treated, 1,000+ of these intravenously No maximum tolerated dose (MTD) reached Safety profile confirmed in a randomized setting Monotherapy Safety Mild toxicities (grade 1 or 2) including • Chills • Cough • Sore throat • Fever • Myal
Slide 6: REOLYSIN: Two Mechanisms of Action
REOLYSIN®: Two Mechanisms of Action 1. In cancer cells with Ras pathway activating mutations (Braf, Kras, Nras, Hras, and EGFR) or p53, REOLYSIN® acts as a directed cytotoxin. 2. REOLYSIN® also interacts with the immune system in at least two known ways, thereby functioning as an immune therapy. 6
Slide 7: Effect of Ras Pathway Activating and/or p53 Mutations on PFS and OS
Effect of Ras Pathway Activating and/or p53 Mutations on Progression Free Survival and Overall Survival Randomized Phase II of non-squamous NSCLC patients with treated with pemetrexed and REOLYSIN®. The test arm patients with Ras pathway activating and/or p53 mutations received greater PFS and O
Slide 8: Effect of Ras Pathway Activating and/or p53 Mutations on PFS and OS
Effect of Ras Pathway Activating and/or p53 Mutations on Progression Free Survival and Overall Survival 8
Slide 9: Cancer and Metastases
Cancer and Metastases Approximately 8.5 million people die from cancer each year, 4 million of them in the developed world. 90% of cancer deaths are due to metastatic disease, primarily in the liver, lung, lymph nodes, and brain. An agent with specific, demonstrated activity in metastatic dise
Slide 10: REOLYSIN: Effect on Liver Metastases
REOLYSIN®: Effect on Liver Metastases REOLYSIN® should have tumour effects on the liver, lymph, lung, and brain metastases in patients based on: 1. Biodistribution patterns; 2. Ability to cross the blood brain barrier in patients with brain metastases; and 3. Genetics. 10
Slide 11: Liver Metastases
Liver Metastases REOLYSIN® was shown in single-arm drug combination studies in head and neck cancer patients to markedly reduce liver metastases in an “unusual” manner. However, single arm study responses must be considered to be anecdotal. 11
Slide 12: Partial Response in Metastatic Liver Tumors – REOLYSIN/Paclitaxel/Carboplatin (Phase 1)
Partial Response in Metastatic Liver Tumors – REOLYSIN®/Paclitaxel/Carboplatin (Phase 1) Pre-Treatment Post-Cycle 2 Post-Cycle 6 • Diagnosis: Metastatic sinu-nasal carcinoma with marked progression of pelvic and hepatic disease • Prior Treatment: Radiotherapy 12
Slide 13: Partial Response in Metastatic Nasopharyngeal Cancer (Phase 2)
Partial Response in Metastatic Nasopharyngeal Cancer – REOLYSIN®/Paclitaxel/Carboplatin (Phase 2) Pre-Treatment Post-Cycle 3 • Treatment History: Radiation (2 cycles); cisplatin, gemcitabine/carboplatin, carboplatin/5-FU (6 cycles); docetaxel (3 cycles) • Liver metastases reduced from 59.4 mm at bas
Slide 14: Randomized Tumour-Specific Data in Head and Neck Cancer (REO 018)
Randomized Tumour-Specific Data: REOLYSIN®/Carboplatin/Paclitaxel Combination in Head and Neck Cancer (REO 018) Loco-regional patients with or without distal metastases experienced a 23% increased reduction in median total tumour volume in the test arm versus the control arm (median from Kaplan-Me
Slide 15: REOLYSIN and Metastases
REOLYSIN® and Metastases REOLYSIN® demonstrated overall metastatic disease tumour reduction in a randomized clinical study. There is now evidence in a randomized study that REOLYSIN® demonstrates liver metastases specific tumour reduction. 15
Slide 16: IND 210 Colorectal Cancer Study: Randomized Tumor Specific Data
IND 210 Colorectal Cancer Study: Randomized Tumor Specific Data Patients were treated with FOLFOX-6/Avastin® plus or minus REOLYSIN®. Patients in the test arm had a 53% objective overall response rate (n=51) versus 35% in the control arm (n=52) (p = 0.06). Patients with liver metastases (with
Slide 17: IND 210 Colorectal Cancer Study: Data by Gender
IND 210 Colorectal Cancer Study: Randomized Tumor Specific Data by Gender Female patients with or without metastases on the test arm had a 63.2% objective response rate (n=19) versus 23.8% on the control arm (n=21) (p=0.0054). These patients also experienced a 51% increased reduction in median t
Slide 18: New Colorectal Cancer Study
New Colorectal Cancer Study Oncolytics Biotech Inc. has filed for a Phase 2 run- in study of FOLFOX-6/Avastin®/REOLYSIN® and pembrolizumab in female patients with colorectal cancer prescreened for mutations in EGFR, Kras, Mras, Hras, BRAF or p53 that is metastatic to the liver. Once we confirm t
Slide 19: IND 211 NSCLC Study: PFS and OS by Gender
IND 211 NSCLC Study: Randomized Progression Free Survival and Overall Survival by Gender Randomized Phase II of non-squamous NSCLC patients with treated with pemetrexed and REOLYSIN®. Female patients on the test arm received greater PFS and OS benefit than female patients on the control arm. M
Slide 20: IND 211 NSCLC Study: PFS and OS by Gender
IND 211 NSCLC Study: Randomized Progression Free Survival and Overall Survival by Gender 20
Slide 21: Manufacturing
Manufacturing Now produced at commercial scale (100L) under cGMP with final formulation Commercial manufacturing agreement in place with Sigma-Aldrich® Fine Chemicals (SAFC) 21
Slide 22: Patent Portfolio
Patent Portfolio More than 400 patents issued worldwide, including 60 US and 20 Canadian More than 70 pending patent applications worldwide Issued patent claims for reovirus cover: Compositions of matter comprising reovirus Pharmaceutical use of reoviruses to treat neoplasia and cellular p
Slide 23: Corporate & Financial
C)ncoryrics www.oncolyticsbiotech.com ONC ONCY ONY
Slide 24: Market & Capital Data
Market & Capital Data (all amounts in CAD) Exchanges OTCQX:ONCYF TSX:ONC FRA:ONY Shares Outstanding (June 30, 2016) 120,233,122 Price Options Outstanding (June 30, 2016) $2.04 7,754,727 (weighted average) Fully Diluted (June 30, 2016) 127,987,849 Total Current Assets (June 30, 2016) $20.41 M 24
Slide 25: Investment Highlights
Investment Highlights Conducting first checkpoint inhibitor and REOLYSIN® study in patients with pancreatic cancer Preparing for registration study Positive safety data for 1,100+ patients Strong intellectual property portfolio More than 400 issued patents worldwide Manufacturing at comm
Slide 26: Corporate Presentation
Corporate Presentation August 2016
Oncolytics Biotech — Investor Presentation (August 2016) on 6ix